Orchestra BioMed Holdings (OBIO) EPS (Weighted Average and Diluted) (2021 - 2026)
Orchestra BioMed Holdings (OBIO) reported EPS (Weighted Average and Diluted) of -$0.33 for Q1 2026, up 32.65% year-over-year from -$0.25 in Q1 2025, and down 226.92% on a QoQ basis from $0.26 in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 6 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.33 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 32.65% year-over-year to -$0.33 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.97 (up 45.51% YoY) and the FY2025 annual result came in at -$1.11, up 33.13% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$0.33 in Q1 2026 per OBIO's latest filing, from $0.26 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $0.26 in Q4 2025 and bottomed at -$0.77 in Q2 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.41 (2024), against an average of -$0.41.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) tumbled 16248.45%; it then soared 160.47% in 2025.
- Tracing OBIO's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.44 in 2022, then gained by 15.91% to -$0.37 in 2023, then dropped by 16.22% to -$0.43 in 2024, then soared by 160.47% to $0.26 in 2025, then tumbled by 226.92% to -$0.33 in 2026.
- Per Business Quant, the three latest OBIO EPS (Weighted Average and Diluted) figures stand at -$0.33 (Q1 2026), $0.26 (Q4 2025), and -$0.4 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -0.33 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.33 |
| Dec 31, 2025 | 0.26 |
| Sep 30, 2025 | -0.40 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.49 |
| Dec 31, 2024 | -0.43 |
| Sep 30, 2024 | -0.41 |
| Jun 30, 2024 | -0.45 |
| Mar 31, 2024 | -0.38 |
| Dec 31, 2023 | -0.37 |
| Sep 30, 2023 | -0.38 |
| Jun 30, 2023 | -0.35 |
| Mar 31, 2023 | -0.40 |
| Dec 31, 2022 | -0.44 |
| Sep 30, 2022 | -0.51 |
| Jun 30, 2022 | -0.77 |
| Mar 31, 2022 | -0.56 |
| Dec 31, 2021 | -0.01 |
| Sep 30, 2021 | 0.00 |
| Jun 30, 2021 | 0.00 |